Mineralocorticoid receptor antagonism limits experimental choroidal neovascularization and structural changes associated with neovascular age-related macular degeneration. [electronic resource]
Producer: 20190205Description: 369 p. digitalISSN:- 2041-1723
- Aged
- Aged, 80 and over
- Angiogenesis Inhibitors -- therapeutic use
- Animals
- Choroid -- drug effects
- Choroidal Neovascularization -- drug therapy
- Drug Compounding -- methods
- Female
- Gene Expression
- Humans
- Intravitreal Injections
- Macular Degeneration -- drug therapy
- Male
- Mice
- Mice, Transgenic
- Microspheres
- Mineralocorticoid Receptor Antagonists -- therapeutic use
- Pilot Projects
- Prospective Studies
- Ranibizumab -- therapeutic use
- Rats, Long-Evans
- Receptors, Mineralocorticoid -- genetics
- Receptors, Vascular Endothelial Growth Factor -- therapeutic use
- Recombinant Fusion Proteins -- therapeutic use
- Spironolactone -- therapeutic use
- Treatment Outcome
- Vascular Endothelial Growth Factor A -- antagonists & inhibitors
No physical items for this record
Publication Type: Journal Article; Research Support, Non-U.S. Gov't
There are no comments on this title.
Log in to your account to post a comment.